PVmed Raises US $14 Million Series A Funding from Cherami, Philips, JHF, COCOCAPITAL, and Strategy Capital

Will Support Rapid Expansion of PVmed's AI Cancer Treatment Product Portfolio

GUANGZHOU, China, Dec. 22, 2022 /PRNewswire/ -- Perception Vision Medical Technologies Co., Ltd. (PVmed), a global artificial intelligence (AI) cancer treatment company, headquartered in Guangzhou, China, has secured US $14 million (RM 100 million) in Series A funding from investors including Cherami Investment Group, Philips, JHF Investment, COCOCAPITAL Corporation, and Strategy Capital. The funding will enable the company to further develop its AI cancer treatment product portfolio and ecosystem. It will also accelerate the adoption of the company's AI-defined cancer surgery and radiotherapy workflow software and hardware products by hospitals and medical technology companies.